155 related articles for article (PubMed ID: 31746254)
1. Cereblon (
Iskierka-Jażdżewska E; Canzian F; Stępień A; Martino A; Campa D; Stein A; Krawczyk-Kuliś M; Rybicka-Ramos M; Kyrcz-Krzemień S; Butrym A; Mazur G; Jurczyszyn A; Zawirska D; Grząśko N; Tomczak W; Subocz E; Wątek M; Pasiarski M; Rymko M; Całbecka M; Druzd-Sitek A; Walewski J; Kruszewski M; Raźny M; Zaucha JM; Dudziński M; Gaj P; Robak T; Warzocha K; Jamroziak K
Leuk Lymphoma; 2020 Mar; 61(3):699-706. PubMed ID: 31746254
[TBL] [Abstract][Full Text] [Related]
2. Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.
Huang SY; Lin CW; Lin HH; Yao M; Tang JL; Wu SJ; Chen YC; Lu HY; Hou HA; Chen CY; Chou WC; Tsay W; Chou SJ; Tien HF
Ann Hematol; 2014 Aug; 93(8):1371-80. PubMed ID: 24687382
[TBL] [Abstract][Full Text] [Related]
3. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
Zhu YX; Braggio E; Shi CX; Bruins LA; Schmidt JE; Van Wier S; Chang XB; Bjorklund CC; Fonseca R; Bergsagel PL; Orlowski RZ; Stewart AK
Blood; 2011 Nov; 118(18):4771-9. PubMed ID: 21860026
[TBL] [Abstract][Full Text] [Related]
4. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J
Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626
[TBL] [Abstract][Full Text] [Related]
5. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.
Heintel D; Rocci A; Ludwig H; Bolomsky A; Caltagirone S; Schreder M; Pfeifer S; Gisslinger H; Zojer N; Jäger U; Palumbo A
Br J Haematol; 2013 Jun; 161(5):695-700. PubMed ID: 23565715
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.
Zhu YX; Kortuem KM; Stewart AK
Leuk Lymphoma; 2013 Apr; 54(4):683-7. PubMed ID: 22966948
[TBL] [Abstract][Full Text] [Related]
7. Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels.
Greenberg AJ; Walters DK; Kumar SK; Rajkumar SV; Jelinek DF
Eur J Haematol; 2013 Dec; 91(6):504-13. PubMed ID: 23992230
[TBL] [Abstract][Full Text] [Related]
8. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.
Broyl A; Kuiper R; van Duin M; van der Holt B; el Jarari L; Bertsch U; Zweegman S; Buijs A; Hose D; Lokhorst HM; Goldschmidt H; Sonneveld P; ;
Blood; 2013 Jan; 121(4):624-7. PubMed ID: 23233657
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment.
Butrym A; Rybka J; Łacina P; Gębura K; Frontkiewicz D; Bogunia-Kubik K; Mazur G
Leuk Res; 2015 Dec; 39(12):1462-6. PubMed ID: 26521987
[TBL] [Abstract][Full Text] [Related]
10. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.
Lopez-Girona A; Mendy D; Ito T; Miller K; Gandhi AK; Kang J; Karasawa S; Carmel G; Jackson P; Abbasian M; Mahmoudi A; Cathers B; Rychak E; Gaidarova S; Chen R; Schafer PH; Handa H; Daniel TO; Evans JF; Chopra R
Leukemia; 2012 Nov; 26(11):2326-35. PubMed ID: 22552008
[TBL] [Abstract][Full Text] [Related]
11. Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma.
Tachita T; Kinoshita S; Ri M; Aoki S; Asano A; Kanamori T; Yoshida T; Totani H; Ito A; Kusumoto S; Komatsu H; Yamagata K; Kubo K; Tohkin M; Fukuda S; Iida S
Cancer Sci; 2020 Apr; 111(4):1333-1343. PubMed ID: 32061138
[TBL] [Abstract][Full Text] [Related]
12. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.
Zhu YX; Braggio E; Shi CX; Kortuem KM; Bruins LA; Schmidt JE; Chang XB; Langlais P; Luo M; Jedlowski P; LaPlant B; Laumann K; Fonseca R; Bergsagel PL; Mikhael J; Lacy M; Champion MD; Stewart AK
Blood; 2014 Jul; 124(4):536-45. PubMed ID: 24914135
[TBL] [Abstract][Full Text] [Related]
13. Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide.
Huang PA; Beedie SL; Chau CH; Venzon DJ; Gere S; Kazandjian D; Korde N; Mailankody S; Landgren O; Figg WD
Sci Rep; 2019 Oct; 9(1):14884. PubMed ID: 31619706
[TBL] [Abstract][Full Text] [Related]
14. Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma.
Gooding S; Ansari-Pour N; Towfic F; Ortiz Estévez M; Chamberlain PP; Tsai KT; Flynt E; Hirst M; Rozelle D; Dhiman P; Neri P; Ramasamy K; Bahlis N; Vyas P; Thakurta A
Blood; 2021 Jan; 137(2):232-237. PubMed ID: 33443552
[TBL] [Abstract][Full Text] [Related]
15. High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.
Jonasova A; Bokorova R; Polak J; Vostry M; Kostecka A; Hajkova H; Neuwirtova R; Siskova M; Sponerova D; Cermak J; Mikulenkova D; Cervinek L; Brezinova J; Michalova K; Fuchs O
Eur J Haematol; 2015 Jul; 95(1):27-34. PubMed ID: 25284710
[TBL] [Abstract][Full Text] [Related]
16. The clinical significance of cereblon expression in multiple myeloma.
Schuster SR; Kortuem KM; Zhu YX; Braggio E; Shi CX; Bruins LA; Schmidt JE; Ahmann G; Kumar S; Rajkumar SV; Mikhael J; Laplant B; Champion MD; Laumann K; Barlogie B; Fonseca R; Bergsagel PL; Lacy M; Stewart AK
Leuk Res; 2014 Jan; 38(1):23-8. PubMed ID: 24129344
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression.
Jung SH; Choi HJ; Shin MG; Lee SS; Hwang EC; Jung TY; Cho MS; Yang DH; Ahn JS; Kim YK; Kim HJ; Lee JJ
Ann Hematol; 2016 Oct; 95(10):1645-51. PubMed ID: 27365142
[TBL] [Abstract][Full Text] [Related]
18. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G
FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201
[TBL] [Abstract][Full Text] [Related]
19. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
Dimopoulos K; Fibiger Munch-Petersen H; Winther Eskelund C; Dissing Sjö L; Ralfkiaer E; Gimsing P; Grønbaek K
Leuk Lymphoma; 2019 Jan; 60(1):180-188. PubMed ID: 29718735
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R
Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
